Novocure's Optune Pax wearable device wins FDA approval for locally advanced pancreatic cancer with gemcitabine + nab-paclitaxel. Phase 3 trial shows improved survival and delayed pain progression.
Viking Therapeutics announces Phase 3 trials for its oral VK2735 obesity pill, showing up to 12.2% weight loss in early tests. Shares jump 9% as company eyes Q3 start.
Vinay Prasad, FDA's biologics director, overruled staff to refuse reviewing Moderna's new mRNA flu vaccine, citing trial design issues. HHS denies overruling occurred amid ongoing debate on vaccine scrutiny.
Upstream Bio's Phase 2 trial for verekitug shows strong results in cutting asthma attacks, but only the every-12-week dose matches rivals. Stock dips as experts weigh in on future plans and competition.
Humana predicts lower 2026 profits due to reduced Medicare ratings, projecting at least $9 per share against Wall Street's $11.92 estimate amid market challenges.
FDA refuses to review Moderna's innovative mRNA flu vaccine over clinical trial design concerns, sending shares down 7%. Company disputes decision citing prior agency approval.
